[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"alzheimers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:alzheimers":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":4},"100647454","robotic-enabled-microsurgical-intervention-for-neurodegenerative-disease---eu-100647454",false,"NCT07708675","Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease - EU","Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease - A European, Prospective, Multi-Center, Open Label Study in Alzheimer's Patients","REMIND-EU","Preoperative Inclusion Criteria:\n\n1. Patient aged 50 to \\\u003C 80 years\n2. Patient has confirmed highly probable or probable Alzheimer's disease according to the International Working Group (IWG) Patient and has a positive core 1 Alzheimer biomarker according to the Alzheimer's Association (AA) criteria\n3. Patient has an MMSE score≥ 18\n4. Investigator deems the candidate acceptable for lymphatic surgery with a robotic-assisted microsurgical anastomosis in accordance with the Symani System's Instructions for Use (IFU)\n5. Patients who are of childbearing potential must agree to use a medically acceptable form of contraception.\n6. Patient or their legally authorized representative agrees to participate in the study, return for all required follow-up visits, complete all study procedures, and has willingly provided written informed consent after receiving all information related to the study, its requirements, and the robotic assisted procedure\n\nIntraoperative Inclusion Criteria:\n\n1\\. Intraoperative imaging confirms lymphatic nodes\u002Fvessels amenable to reconstruction\n\nPreoperative Exclusion Criteria:\n\n1. Patient (or their legally authorized representative) is unwilling to provide informed consent\n2. Patient has suspected dementia of other type, e.g., Lewy body, frontotemporal disorder, vascular, etc.\n3. History of head and neck radiation exposure\n4. Patient with severe kidney disease (GFR \\\u003C30 mL\u002Fmin\u002F1.73m2)\n5. Patient with acute kidney injury\n6. Active systemic infection under treatment with intravenous antibiotics\n7. Patient has a modified Rankin Score (mRS) of \\>4\n8. Documented history of clinically significant diagnosis of cardiovascular, digestive, respiratory, endocrine, or central nervous system disorders, untreated sleep apnea, previous mental disorders, or other disorders that may significantly affect the data collection or the ability to comply with the protocol per the investigator's discretion\n9. Known history of significant bleeding, coagulopathy, or Von Willebrand's disease\n10. Patient with an active cancer diagnosis and\u002For currently receiving treatment for cancer or has received treatment within the past 6 months\n11. Patient is currently receiving treatment or has been treated with anti-amyloid-beta monoclonal antibody therapy within the past 6 months\n12. Patient has contraindication for MRI\n13. Currently enrolled in any other investigational clinical studies that the investigator believes may impact patient safety or study outcomes\n14. Patient is ineligible to participate for other reasons in the judgment of the investigator\n\nIntraoperative Exclusion Criteria:\n\n1\\. Any presenting condition discovered intraoperatively that, in the opinion of the investigator, would make participating in this study not in the patient's best interest","ALL","50 Years","80 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"NA","The objective of this study is to evaluate the safety and feasibility of the Symani System and microsurgical techniques in the deep Cervical Lymph Node (dCLN) region in patients with confirmed Alzheimer's disease.",[28],"Alzheimer's",[30,31,32,33,34,35,36,37,38],"Dementia","Brain Diseases","Central Nervous System Diseases","Nervous System Diseases","Tauopathies","Neurodegenerative Diseases","Neurocognitive Disorders","Mental Disorders","Alzheimer Disease","NOT_YET_RECRUITING","2026-07-15",{"date":42,"type":43},"2026-07-16","ACTUAL",{"date":45,"type":22},"2026-10-01",{"date":47,"type":22},"2029-03-01",{"name":49,"class":50},"MMI (Medical Microinstruments, Inc.)","INDUSTRY",{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":17,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":23,"phases":63,"briefSummary":64,"conditions":65,"keywords":70,"overallStatus":75,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":86},"100489597","chronic-treatment-of-alzheimers-disease-by-gamma-light-and-sound-therapy-100489597","NCT05655195","Chronic Treatment of Alzheimer's Disease by Gamma Light and Sound Therapy","Chronic Treatment of Alzheimer's Disease With Gamma Frequency Stimulation","Inclusion Criteria:\n\nSubjects may be enrolled into the study if they meet all of the following criteria:\n\n* Subject is between the ages of 65 - 100.\n* Subject must have mild Alzheimer's disease with a Mini Mental State Exam (MMSE) score of 19-26.\n* Subject is willing to sign informed consent document.\n* If subject is deemed to not have capacity to sign the informed consent, he\u002Fshe will need a legally authorized representative to provide surrogate consent.\n* Able to complete the 1st month of at home stimulation at their primary residence. If subjects plan to spend more than 1 week away from their primary residence during the trial, their inclusion must be assessed by the research team.\n\nExclusion Criteria:\n\nSubjects who meet any of the following conditions will not be enrolled in the study:\n\n* Subjects who do not have healthcare.\n* Subjects who are currently taking amyloid reducing therapy.\n* Subjects who have \\> 4 cerebral microbleeds or 1 macrobleed in their brain\n* Active treatment on a dosage of one or more psychiatric agents (e.g. antidepressants, antipsychotics, etc) for LESS THAN three months (a stable dose for greater than or equal to three months is ok).\n* Subjects who are actively diagnosed with cancer and undergoing cancer-related treatments\n* Subjects who are being treated with N-methyl-D-aspartate (NMDA) receptor antagonists (eg. Memantine).\n* Subjects on medications that lower seizure threshold such as wellbutrin, ciprofloxacin, levofloxacin, etc.\n* Subjects with history of seizure or epilepsy\n* Subjects with clinically significant suicide risk and\u002For suicide attempt in the past 1 year.\n* Subjects with behavioral problems such as aggression\u002Fagitation\u002Fimpulsivity that might interfere with their ability to comply with protocol.\n* Subjects with untreated or unstable depression\n* Active treatment with one or more anti-epileptic agent.\n* Subjects who have had a stroke within the past 24 months.\n* Subjects who have had eye surgery in the last 3 months or are scheduled to have eye surgery in the next 6 months (during the study)\n* Subjects diagnosed with migraine headache.\n* Subjects who have an active implantable medical device including but not limited to implantable cardioverter defibrillator (ICD), deep brain stimulator (DBS), cardiac pacemaker, and\u002For sacral nerve stimulator.\n* Subjects who have profound hearing or visual impairment.\n* Subjects who have a life expectancy of less than 2 years.\n* Subjects who are pregnant.\n* Current or past history of any neurological disorder other than dementia, such as epilepsy, stroke, progressive neurologic disease (e.g. multiple sclerosis) or intracranial brain lesions; and history of previous neurosurgery or head trauma that resulted in residual neurologic impairment.",true,"65 Years","100 Years",{"count":62,"type":22},60,[25],"Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits amyloid and tau) in the brain, and changes in the gamma frequency band on EEG. The investigator's lab found that boosting gamma waves in AD mouse models using light and sound stimulation at 40Hz not only reduced amyloid and tau in the brain, but also improved memory. The investigators developed a light and sound device for humans that stimulates the brain at 40Hz that can be used safely at home. For the present study, 60 participants with mild Alzheimer's disease will be enrolled and will use this light and sound device at-home daily for 6-months. Investigators will measure changes in brain waves with EEG, blood biomarkers, the microbiome via fecal samples, functional and structural MRI scans, memory and cognitive testing, and questionnaires at 3 in-person visits throughout the study. After the 6-month time point, participants will have the option of continuing in the study for at least one year and completing yearly study visits. This study will provide critical insight into extended therapy involving non-invasive 40Hz sensory stimulation as a possible therapeutic strategy for mild to moderate Alzheimer's disease.",[38,66,67,68,28,69],"Alzheimer Disease, Early Onset","Alzheimer Disease, Late Onset","Alzheimer's Disease (Incl Subtypes)","Alzheimer's Disease",[28,71,72,73,74],"Alzheimer","Alzheimer's disease","Light and Sound Stimulation","Tactile Stimulation","RECRUITING","2026-03-24",{"date":78,"type":43},"2026-03-30",{"date":80,"type":43},"2022-12-14",{"date":82,"type":22},"2026-09-01",{"name":84,"class":85},"Massachusetts Institute of Technology","OTHER",1]